Teva: Berkshire Is Barking Up The Wrong Tree

Warren Buffett of Berkshire Hathaway. Source: medium.com

Teva (TEVA) reported more disappointing results for Q4. Revenue and EBITDA fell Y/Y by 16% and 29%, respectively. Somehow Berkshire Hathaway (BRK.B), (BRK.A) thought this was a good time to invest in the struggling generics drug giant:

After the market closed Wednesday, a filing from Buffett's Berkshire Hathaway Inc. disclosed that it made only one new investment during the latest quarter ... Teva's ADRs had collapsed by 65 percent between last August and November, as its best-selling product -- Copaxone, a medicine for multiple sclerosis -- met with competition from copycat therapies. It doesn't help that Teva, now a junk-grade issuer, is deep in debt after overpaying for Allergan Plc's generic-drug business in a $40 billion deal that closed in August 2016. Most analysts aren't confident that the business will make a substantial recovery this year after Teva's own management -- which has seen much turnover in recent years -- gave a disappointing outlook.

READ FULL ARTICLE HERE